Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
监事会关于第八届监事会第三次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review opinions on various company reports and proposals, including the 2019 annual report, 2020 first quarter report, profit distribution plan, internal control self-evaluation report, and stock repurchase and cancellation related to restricted shares. It contains detailed audit opinions on these reports and proposals, indicating it is an audit or supervisory review document rather than the reports themselves. The document length is 7177 characters, which is substantial and contains substantive content, not just an announcement. The focus on audit opinions and compliance with regulations aligns with an Audit Report / Information filing rather than an Annual Report or Interim Report. Therefore, the document is best classified as an Audit Report / Information (AR). Q1 2020
2020-04-27 Chinese
2019年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2019 Annual Report Summary" of Shenzhen Haier Bioengineering Co., Ltd. It contains detailed financial data for the year 2019, including revenue, net profit, segment business descriptions, accounting policy changes, bond information, and management discussion and analysis. The length is substantial (15,000 characters), and it includes comprehensive financial statements and analysis rather than just an announcement or a brief summary. The content aligns with the characteristics of an Annual Report (10-K) as it covers the full fiscal year performance, financial data, business overview, and accounting policies. Therefore, the document is classified as an Annual Report (10-K). FY 2019
2020-04-27 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 First Quarter Report" of Shenzhen Haier Bioengineering Co., Ltd. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, and management commentary on financial performance and significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (the first quarter of 2020) clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-27 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 年第一季度报告正文" which translates to "2020 First Quarter Report Main Text." It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the first quarter of 2020. It also includes management statements, shareholder information, and explanations of financial changes during the quarter. The length of the document (5944 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-27 Chinese
独立董事关于第八届董事局第七次会议相关事项的专项说明和独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' special statement and independent opinions regarding various company matters related to the 8th Board's 7th meeting. It covers topics such as external guarantees, profit distribution proposals, bad debt write-offs, internal control self-evaluation, audit firm reappointment, related party transactions, stock repurchase price adjustments, and capital increase by a subsidiary. The document references compliance with regulatory guidelines and company bylaws, and it is dated April 26, 2020. The content is focused on board-level oversight and opinions on governance and financial matters rather than presenting full financial statements or detailed financial results. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement or certification. The document fits best under Board/Management Information (MANG) as it relates to board opinions and governance matters discussed in a board meeting context.
2020-04-27 Chinese
关于2019年度核销坏账及计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the 2019 annual write-off of bad debts and provision for asset impairment. It details the accounting standards applied, the amounts of impairment losses and bad debt write-offs, and includes opinions from independent directors and the supervisory board. The document is relatively short (3007 characters) and focuses on specific accounting decisions and disclosures rather than presenting a full annual report or comprehensive financial statements. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about impairment provisions and bad debt write-offs, which fits best under Regulatory Filings (RNS) as it does not meet the criteria for other more specific categories and is not a full report itself.
2020-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.